RxDoctor Payments Data

John Barbara

Medical · Gilroy, CANPI 1972882546

Payments from drug & device makers

$8,624in general payments, 2019–2025

Across 423 payments — averaging $20.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Boehringer Ingelheim$1K
  • Novo Nordisk$871
  • GSK$767
  • Amgen$741
  • Pfizer$586
  • plus $3K from 29 others

What the payments were for

  • Food & beverage$8,593100%
  • Education$310%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,624 in reported general payments places this provider in the 90th percentile of 2,087 medical providers in California.

See all medical providers in California

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin149$169,069
OzempicSemaglutide98$111,280
Trelegy ElliptaFluticasone/Umeclidin/Vilanter67$75,214
EliquisApixaban58$64,631
JanuviaSitagliptin Phosphate43$61,344
TrulicityDulaglutide27$38,957
MounjaroTirzepatide34$35,583
Repatha SureclickEvolocumab24$29,588
LinzessLinaclotide31$25,856
NuedextaDextromethorphan Hbr/Quinidine13$20,126
FarxigaDapagliflozin Propanediol15$17,881
Alosetron Hcl12$12,649
VascepaIcosapent Ethyl19$11,187
Tresiba Flextouch U-200Insulin Degludec20$10,346
Rosuvastatin Calcium480$9,330

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$1,139$169,069149 claims
Novo NordiskOzempic$871$111,28098 claims
GSKTrelegy Ellipta, Breo Ellipta$767$82,06379 claims
Lilly USA, LLCTrulicity, Mounjaro$337$74,54061 claims
PfizerEliquis$586$64,63158 claims
MerckJanuvia$409$61,34443 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$1,473$29,36042 claims
AbbVieLinzess$389$25,85631 claims
Avanir Pharmaceuticals, Inc.Nuedexta$52$20,12613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,087 medical providers in California.

Other medical in Gilroy

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →